The use of biologic medications for the treatment of cutaneous immune-related adverse events secondary to immune checkpoint inhibitors: A single-institution real-life study

• Jade N. Young, BS,
• Hannah Verma, BA,
• Nour El Kashlan, MD,
• Dina Poplausky, BA,
• Angela J. Lamb, MD,
• Emma Guttman-Yassky, MD, PhD,
• Nicholas Gulati, MD, PhD

Affiliations

Jade N. Young, BS

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York

Hannah Verma, BA

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York

Nour El Kashlan, MD

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York

Dina Poplausky, BA

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York

Angela J. Lamb, MD

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York

Emma Guttman-Yassky, MD, PhD

Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York

Nicholas Gulati, MD, PhD

Correspondence to: Nicholas Gulati, MD, PhD, Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th Street, New York, NY, 10029.; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York